Lineweaver Wealth Advisors LLC Boosts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Lineweaver Wealth Advisors LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 96.6% during the fourth quarter, HoldingsChannel reports. The fund owned 3,192 shares of the medical research company’s stock after buying an additional 1,568 shares during the period. Lineweaver Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,661,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Robeco Schweiz AG grew its holdings in shares of Thermo Fisher Scientific by 7.0% during the 4th quarter. Robeco Schweiz AG now owns 165,544 shares of the medical research company’s stock worth $86,121,000 after purchasing an additional 10,902 shares during the period. Convergence Financial LLC boosted its stake in Thermo Fisher Scientific by 3.5% during the fourth quarter. Convergence Financial LLC now owns 3,045 shares of the medical research company’s stock worth $1,584,000 after buying an additional 103 shares during the period. Cable Hill Partners LLC increased its position in shares of Thermo Fisher Scientific by 14.8% during the fourth quarter. Cable Hill Partners LLC now owns 1,288 shares of the medical research company’s stock valued at $670,000 after acquiring an additional 166 shares during the last quarter. Heritage Investors Management Corp lifted its holdings in shares of Thermo Fisher Scientific by 13.1% in the 4th quarter. Heritage Investors Management Corp now owns 48,904 shares of the medical research company’s stock worth $25,441,000 after acquiring an additional 5,651 shares during the last quarter. Finally, SRN Advisors LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $237,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the transaction, the chief executive officer now owns 111,192 shares of the company’s stock, valued at $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 20,125 shares of company stock valued at $11,231,699. Insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Citigroup upped their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a “neutral” rating in a research note on Friday, January 31st. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a report on Friday, January 10th. Wells Fargo & Company boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Finally, Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $656.86.

Thermo Fisher Scientific Stock Down 1.2 %

TMO stock opened at $533.00 on Thursday. The company’s 50 day moving average is $549.14 and its two-hundred day moving average is $566.23. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market cap of $201.08 billion, a P/E ratio of 32.24, a PEG ratio of 2.99 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to buy up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.